Omnicell Inc
NASDAQ:OMCL
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Omnicell Inc
NASDAQ:OMCL
|
1.6B USD |
Loading...
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
Loading...
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
28.6B USD |
Loading...
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
12.3B AUD |
Loading...
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.1T JPY |
Loading...
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
4.7B USD |
Loading...
|
|
| SE |
|
Sectra AB
STO:SECT B
|
35.5B SEK |
Loading...
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
3.9B USD |
Loading...
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
25.2B CNY |
Loading...
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
281.4B INR |
Loading...
|
|
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Omnicell Inc
Glance View
Omnicell Inc. stands at the intersection of healthcare and technology, sculpting the landscape of medication management systems with its innovative spirit. Founded in 1992, Omnicell has evolved from a small enterprise into a leading provider of automated solutions for medication and supply dispensing, inventory management, and analytics. The company’s core offering, its automated dispensing systems, reshapes how hospitals, pharmacies, and healthcare providers manage medications. By utilizing cutting-edge technology, Omnicell improves efficiency, reduces medication errors, and cuts down on healthcare costs. These systems are embedded in the workflow of healthcare facilities, ensuring that medication management becomes seamless, thus elevating patient safety and clinical outcomes. Revenue streams flow robustly from both product sales and associated services. Omnicell garners income by selling its advanced hardware systems, which include everything from pharmacy carousels to medication robotic systems, and supplements these sales with software solutions that offer predictive analytics and inventory optimization. Beyond the initial sale, a significant part of their business model includes recurring revenue through service contracts, software updates, and customer support. This dual approach not only ensures a steady cash flow but also strengthens customer relationships by consistently providing value over time. As the healthcare industry increasingly leans on technology for streamlined operations and cost management, Omnicell’s strategic positioning allows it to capitalize on the demand for sophisticated medication management solutions.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Omnicell Inc is 42.5%, which is below its 3-year median of 43.2%.
Over the last 3 years, Omnicell Inc’s Gross Margin has decreased from 46.1% to 42.5%. During this period, it reached a low of 41.4% on Sep 30, 2024 and a high of 46.1% on Dec 31, 2022.